Despite its benefits, MammaPrint does have some limitations. It is not suitable for all breast cancer patients, particularly those with advanced-stage cancer or tumors larger than 5cm. Moreover, the test may not be covered by all insurance plans, potentially leading to out-of-pocket costs for some patients. Additionally, while MammaPrint provides valuable risk stratification, it should be used in conjunction with other clinical factors and physician judgment when making treatment decisions.
